Skip to main content

Table 1 Characteristics of included studies

From: Antibiotic prophylaxis in primary and revision shoulder replacement: a systematic review

Author Year Study design (Oxford Center of EBM level) Population Patients with ATB therapy Shoulder
Involved
Age (mean) Gender (m/f) Microorganism Type of infection (a/c) * Time of follow up Antibiotic
Pérez-Prieto[19] 2016 Prospective randomized and controlled study
(I)
28 28 3 74 15/13   A = 14;
C = 14
  Cefalosporin
Glycopeptide
Kong Koh,[20] 2016 Randomized study
(I)
30 30 30 74 7/23 P. acnes   9- months Cefazolin
Gentamicin
Lutz[21] 2005 Retrospective study
II
52 35 15 51,8 37/15 P. acnes   average follow-up 37.1 months Clindamycin–Ofloxacin (n = 14PZ)
Rifampicin–Ofloxacin(n = 6PZ)
Clindamycin–Rifampicin (n = 3PZ) Cloxacillin–Ofloxacin(n = 2)
Rrifampicin–Pristinamycin (n = 2PZ)
Ceftriaxone–pristinamycin(n = 1PZ) Cefepime–Ofloxacin (n = 1PZ)
eicoplanin–Rifampicin (n = 1PZ)
Clindamycin–Fusidic Acid (n = 1PZ)
Clindamycin monotherapy(n = 1PZ) Vancomycin–Ceftazidime–Ciprofloxacin(n = 1PZ)
Opric a[22] 2004 Retrospective study
(II)
328 304 304    P. acnes    Clindamycin
Erythromycin
Tetracycline
Linezolyd
Benzypenicillin
Vancomycin
Matse n[23] 2015 Prospective study
(I)
10 10 10 range 11–58 10/0 P. acnes    Ceftriaxone
Vancomycin
Parad a[24] 2018 An on-line survey
(V)
84 62 62    P. acnes    Cefazolin
Vancomicin
Clindamycin
Al-Mayahi[25] 2015 Case-control study
(III)
2740 1167 2740 57   S. aureus    Quinolone
Beta-Lactam
Long-Acting Agent (Vancomycin, Teicoplanin, Ceftriaxone, Ertapenem)